Tenor Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$255 Hold
50,000
– – ﹤0.01% 592
2026
Q2
$1.52K Hold
50,000
– – ﹤0.01% 533
2026
Q1
$1.02K Hold
50,000
– – ﹤0.01% 492
2025
Q4
$1.3K Hold
50,000
– – ﹤0.01% 424
2025
Q3
$1.76K Hold
50,000
– – ﹤0.01% 383
2025
Q2
$2.04K Hold
50,000
– – ﹤0.01% 342
2025
Q1
$3.82K Hold
50,000
– – ﹤0.01% 267
2024
Q4
$1.7K Hold
50,000
– – ﹤0.01% 275
2024
Q3
$1.58K Buy
+50,000
New +$2.9K ﹤0.01% 270

Other funds holding SLXNW

Tenor Capital Management's SLXNW Position: Q3 2026 in Review

Tenor Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q3 2026 at 50,000 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Tenor Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.82K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q3 2026.

  • Tenor Capital Management held 50,000 shares of Silexion Therapeutics Warrant worth $255 as of Q3 2026.
  • Tenor Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q3 2026.
  • Silexion Therapeutics Warrant made up ﹤0.01% of Tenor Capital Management's portfolio in Q3 2026, its #592 holding.
  • Tenor Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 9 quarters since.
  • Tenor Capital Management's Silexion Therapeutics Warrant position peaked at $3.82K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q3 2026.

Based on Tenor Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.